Read more about our commitment in Oncology


Targeting Direct Hits to Cancer Cells

Learn more »

Striving for the Right Tools to Fight Brain Tumors with Kyle Holen

Learn more »

‘Patients Need To Move On With Their Lives’: Q&A With Lori Styles, M.D., Pharmacyclics

Learn more »



View all of our Oncology press releases:

Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer Patients

NORTH CHICAGO, Ill., Nov. 21, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that the American Society of Hematology (ASH) has accepted data from the Phase 3 MURANO study evaluating venetoclax tablets in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), as an oral, late-breaking presentation during the upcoming 59th ASH Annual Meeting & Exposition, December 9-12, in Atlanta, GA. The abstract is one of six late-breaking abstracts accepted for presentation at the meeting.

AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 18, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced today that they have entered an immuno-oncology research collaboration. The goal of the collaboration is to incorporate Harpoon's tri-specific T-cell activating construct (TriTAC™) platform with AbbVie's research-stage immuno-oncology targets to develop novel cancer therapeutics.

On-and-Off Switches for More Precise Medicines Against Cancer

Protein engineering is allowing researchers to program antibodies so they turn on and off in certain conditions to more precisely target tumors.

AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors

NORTH CHICAGO, Ill. and NEW YORK, Sept. 22, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC). 

Shifting the Battlefield Strategy in the War on Cancer

A greater understanding of what makes each individual cancer unique could shape the way it’s treated in the era of personalized medicine.